About MannKind

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes.

In addition, MannKind is applying our novel technologies and services to support partner development efforts. More >

 

 

Spotlight

MannKind Announces FDA approval of AFREZZA® a novel,rapid acting inhaled insulin More >

News & Events

   
Jun 27, 2014 MannKind Corporation Announces FDA Approval of AFREZZA(R); A Novel, Rapid-Acting... More >
May 27, 2014 MannKind to Present at Upcoming Conferences More >
May 12, 2014 MannKind Corporation Reports 2014 First Quarter Financial Results More >